Danaher
Market Cap
US$98.3b
Last Updated
2019/10/22 23:34 UTC
Data Sources
Company Financials +
Executive Summary
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
Snowflake
Fundamentals
Adequate balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has Danaher's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-0.4%
DHR
-1.6%
US Medical Equipment
0.07%
US Market
1 Year Return
40.7%
DHR
13.8%
US Medical Equipment
8.9%
US Market
Return vs Industry: DHR exceeded the US Medical Equipment industry which returned 13.8% over the past year.
Return vs Market: DHR exceeded the US Market which returned 8.9% over the past year.
Shareholder returns
| DHR | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.4% | -1.6% | 0.07% |
| 30 Day | -6.4% | -4.3% | -0.3% |
| 90 Day | -3.9% | -4.3% | -1.6% |
| 1 Year | 41.5%40.7% | 14.7%13.8% | 11.3%8.9% |
| 3 Year | 77.2%74.0% | 70.7%65.6% | 46.3%36.8% |
| 5 Year | 133.6%71.9% | 117.3%93.5% | 62.1%44.3% |
Price Volatility Vs. Market
How volatile is Danaher's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Danaher Corporation's (NYSE:DHR) ROE Can Tell Us3 weeks ago | Simply Wall St
Want To Invest In Danaher Corporation (NYSE:DHR)? Here's How It Performed Lately1 month ago | Simply Wall St
Here's What We Think About Danaher Corporation's (NYSE:DHR) CEO PayValuation
Is Danaher undervalued compared to its fair value and its price relative to the market?
39.63x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DHR ($137.08) is trading above our estimate of fair value ($114.97)
Significantly Below Fair Value: DHR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DHR is good value based on its PE Ratio (39.6x) compared to the Medical Equipment industry average (41.8x).
PE vs Market: DHR is poor value based on its PE Ratio (39.6x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: DHR is poor value based on its PEG Ratio (2.4x)
Price to Book Ratio
PB vs Industry: DHR is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (3.7x).
Next Steps
Future Growth
How is Danaher forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
16.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DHR's forecast earnings growth (16.5% per year) is above the savings rate (2.7%).
Earnings vs Market: DHR's earnings (16.5% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: DHR's earnings are forecast to grow, but not significantly.
Revenue vs Market: DHR's revenue (7.2% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: DHR's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DHR's Return on Equity is forecast to be low in 3 years time (13.1%).
Next Steps
Past Performance
How has Danaher performed over the past 5 years?
4.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: DHR's earnings have grown by 4% per year over the past 5 years.
Accelerating Growth: DHR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DHR had negative earnings growth (-8.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (28.2%).
Return on Equity
High ROE: DHR's Return on Equity (7.7%) is considered low.
Return on Assets
ROA vs Industry: DHR's Return on Assets is below or equal to the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: DHR has significantly improved its Return on Capital Employed over the past 3 years.
Next Steps
Financial Health
How is Danaher's financial position?
Financial Position Analysis
Short Term Liabilities: DHR's short term assets ($11.6B) exceeds its short term liabilities ($5.0B)
Long Term Liabilities: DHR's short term assets (11.6B) do not cover its long term liabilities (16.1B)
Debt to Equity History and Analysis
Debt Level: DHR's debt to equity ratio (32%) is considered satisfactory
Reducing Debt: DHR's debt to equity ratio has increased from 12.9% to 32% over the past 5 years.
Debt Coverage: DHR's debt is well covered by operating cash flow (39.1%).
Interest Coverage: DHR's interest payments on its debt are well covered by EBIT (49.3x coverage).
Balance Sheet
Inventory Level: DHR has a low level of unsold assets or inventory.
Debt Coverage by Assets: DHR's debt is covered by short term assets (assets are 1.125800x debt).
Next Steps
Dividend
What is Danaher's current dividend yield, its reliability and sustainability?
0.50%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: DHR's dividend (0.5%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: DHR's dividend (0.5%) is low compared to the top 25% of dividend payers in the US market (3.68%).
Stable Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: DHR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DHR is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DHR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Danaher's salary, the management and board of directors tenure and is there insider trading?
2.8yrs
Average management tenure
CEO
Tom Joyce (58yo)
5.1yrs
Tenure
US$15,361,041
Compensation
Mr. Thomas P. Joyce, Jr., also known as Tom, has been the Chief Executive Officer and President of Danaher Corp. since September 9, 2014. Mr. Joyce served as Executive Vice President of Danaher Corporation ...
CEO Compensation Analysis
Compensation vs. Market: Tom's total compensation ($USD15.36M) is about average for companies of similar size in the US market ($USD11.18M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: DHR's management team is considered experienced (2.8 years average tenure).
Board Age and Tenure
16.3yrs
Average Tenure
68yo
Average Age
Experienced Board: DHR's board of directors are seasoned and experienced ( 16.3 years average tenure).
Insider Trading
Insider Buying: DHR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Co-Founder & Director |
| Shares | 2,500 |
| Max Price | US$139.52 |
| Entity | Individual |
| Shares | 1,010 |
| Max Price | US$144.04 |
| Entity | Individual |
| Role | Chief Accounting Officer Chief Accounting Officer & Senior VP |
| Shares | 657 |
| Max Price | US$143.19 |
| Entity | Individual |
| Shares | 8,350 |
| Max Price | US$129.92 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President |
| Shares | 7,534 |
| Max Price | US$131.27 |
| Entity | Individual |
| Shares | 3,091 |
| Max Price | US$132.23 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 14,454 |
| Max Price | US$132.79 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President |
| Shares | 7,726 |
| Max Price | US$132.41 |
| Entity | Individual |
| Role | Member of the Board of Directors Co-Founder & Director |
| Shares | 1,900 |
| Max Price | US$130.78 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President |
| Shares | 10,772 |
| Max Price | US$132.05 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Executive VP |
| Shares | 5,020 |
| Max Price | US$131.02 |
| Entity | Individual |
| Shares | 10,209 |
| Max Price | US$126.14 |
| Entity | Individual |
| Role | Chief Accounting Officer Chief Accounting Officer & Senior VP |
| Shares | 2,822 |
| Max Price | US$127.01 |
| Entity | Individual |
| Shares | 4,534 |
| Max Price | US$127.25 |
| Entity | Individual |
| Shares | 1,564 |
| Max Price | US$127.22 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President |
| Shares | 11,971 |
| Max Price | US$127.14 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President |
| Shares | 17,060 |
| Max Price | US$127.42 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President |
| Shares | 11,000 |
| Max Price | US$102.21 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 5,212 |
| Max Price | US$103.89 |
| Entity | Individual |
| Role | Senior Key Executive Executive Vice President |
| Shares | 29,784 |
| Max Price | US$98.15 |
Ownership Breakdown
Management Team
Steven Rales (68yo)
Co-Founder & Chairman
- Tenure: 35.8yrs
Dan Comas (55yo)
Executive Vice President
- Tenure: 0.8yrs
- Compensation: US$6.85m
Dan Daniel (54yo)
Executive Vice President
- Tenure: 11.3yrs
- Compensation: US$6.17m
Mitchell Rales (62yo)
Co-Founder & Director
- Tenure: 36.8yrs
Bob Lutz (61yo)
Chief Accounting Officer & Senior VP
- Tenure: 9.7yrs
Tom Joyce (58yo)
CEO, President & Director
- Tenure: 5.1yrs
- Compensation: US$15.36m
Joakim Weidemanis (49yo)
Executive Vice President
- Tenure: 1.9yrs
- Compensation: US$4.44m
Matt Gugino
Vice President of Investor Relations
- Tenure: 0yrs
Rainer Blair (55yo)
Executive Vice President
- Tenure: 2.8yrs
- Compensation: US$5.09m
Matt McGrew (47yo)
CFO & Executive VP
- Tenure: 0.8yrs
Board Members
Alan Spoon (68yo)
Independent Director
- Tenure: 20.8yrs
- Compensation: US$279.82k
Steven Rales (68yo)
Co-Founder & Chairman
- Tenure: 35.8yrs
Donald Ehrlich (81yo)
Lead Independent Director
- Tenure: 0yrs
- Compensation: US$329.82k
Walter Lohr (75yo)
Independent Director
- Tenure: 36.8yrs
- Compensation: US$279.82k
Mitchell Rales (62yo)
Co-Founder & Director
- Tenure: 36.8yrs
John Schwieters (79yo)
Independent Director
- Tenure: 16.3yrs
- Compensation: US$304.82k
Elias Zerhouni (68yo)
Independent Director
- Tenure: 10.8yrs
- Compensation: US$279.82k
Linda Filler (59yo)
Independent Director
- Tenure: 13.8yrs
- Compensation: US$294.82k
Tom Joyce (58yo)
CEO, President & Director
- Tenure: 5.1yrs
- Compensation: US$15.36m
Teri List-Stoll (56yo)
Independent Director
- Tenure: 8.1yrs
- Compensation: US$279.82k
Company Information
Danaher Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Danaher Corporation
- Ticker: DHR
- Exchange: NYSE
- Founded: 1969
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$98.337b
- Shares outstanding: 717.37m
- Website: https://www.danaher.com
Number of Employees
Location
- Danaher Corporation
- 2200 Pennsylvania Avenue NW
- Suite 800W
- Washington
- District Of Columbia
- 20037
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DHR | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Nov 1969 |
| DAP | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 1969 |
| DHR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Nov 1969 |
| DHR | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Nov 1969 |
| 0R2B | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Nov 1969 |
| DHRC | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Nov 1969 |
| DHER34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR REPR 1/4 COM SHS USD0.01 | BR | BRL | Jul 2015 | |
| DHR.PRA | NYSE (New York Stock Exchange) | 4.75 MND CV PFD | US | USD | Feb 2019 |
Biography
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company’s Life Sciences segment provides mass spectrometers; ce ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/22 23:34 |
| End of Day Share Price | 2019/10/22 00:00 |
| Earnings | 2019/06/28 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.